



# UK Interdisciplinary Breast Cancer Symposium

## Programme

22 - 23 January 2024  
ICC Birmingham

AstraZeneca 

 Daiichi-Sankyo

AstraZeneca 

**EXACT  
SCIENCES**

*Lilly* | ONCOLOGY

 **MSD**

 **NOVARTIS**

 **Roche**

 **GILEAD**  
Oncology

 **MENARINI**  
group

 **Stemline**  
A Menarini Group Company

 **veracyte.**



# UK Interdisciplinary Breast Cancer Symposium

## Programme - Monday 22 January 2024

8:00AM - 9:00AM	Registration			
9:00AM - 9:15AM	Opening Andreas Makris, Chair of the UKIBCS Organising Committee, UK Delyth Morgan, CEO of Breast Cancer Now, UK Lesley Stephen, Patient Advocate, UK Hall 1			
9:15AM - 10:15AM	Review of the year Chair: Andreas Makris Basic science/translational Rob Clarke, University of Manchester, Manchester, UK Update on the key developments in early breast cancer treatment in 2023 Cliona Kirwan, University of Manchester & Manchester University Foundation Trust, Manchester, UK Metastatic breast cancer Iain MacPherson, University of Glasgow, Glasgow, UK Hall 1			
10:15AM - 10:45AM	Plenary Lecture: Clinical implications of late recurrence/dormancy (Cridlan Lecture) Dan Hayes, University of Michigan, Ann Arbor, USA Introduced by Gillian Ross, Royal Marsden NHS Trust, London, UK Hall 1			
10:45AM - 11:15AM	Morning refreshment break, exhibition & poster viewing			
Parallel Session 1 11:15AM - 12:25PM	Session 1.1 - Tailoring surgery in early breast cancer Chairs: Leena Chagla and Ramsay Cutress Mastectomy versus breast conservation plus radiotherapy Jana de Boniface, Karolinska Institute / Capio St. Göran's Hospital, Stockholm, Sweden Surgery for multi-focal disease Judy Boughie, Mayo Clinic, Rochester, USA Optimising oncoplastic breast surgery Shelley Potter, Bristol Medical School, Bristol, UK Hall 1	Session 1.2 - Tumour cell dormancy Chairs: Ingunn Holen and Julia Gee Modelling dormancy Marco Montagner, University of Padua, Padua, Italy Regulation of dormancy by natural killer cells Mohamed Bentires-Alj, University Hospital Basel, Basel, Switzerland The microenvironment regulates escape from dormancy Clare Isacke, Institute of Cancer Research, London, UK Hall 11	Session 1.3 - Targeting HER2 in metastatic breast cancer Chairs: Iain MacPherson and Lesley Stephen HER2 +ve metastatic breast cancer: past, present and future David Cameron, University of Edinburgh, Edinburgh, UK Biological heterogeneity of HER2 +ve metastatic breast cancer: clinical implications Maggie Cheang, Institute of Cancer Research, London, UK What is HER2 low and what are the clinical implications? Abeer Shaaban, Queen Elizabeth Hospital Birmingham & University of Birmingham, Birmingham, UK Hall 5	Session 1.4 - Living with and beyond breast cancer Chairs: Lesley Turner and Claire Ryan Fear of cancer recurrence and progression: Early recognition, support and validation Susanne Cruickshank, Royal Marsden Hospital, London, UK Sexual Intimacy and breast cancer Isabel White, Perci Health Ltd, London, UK The psychological and psychiatric sequelae of breast cancer Asanga Fernando, St George's Hospital, London, UK Hall 8
12:25PM - 1:45PM	Lunch, exhibition & poster viewing			
Satellite Symposia 12:40PM - 1:40PM	Satellite Symposium - AstraZeneca Hall 8	Satellite Symposium - Lilly Hall 5	Satellite Symposium - Exact Science Hall 11	
1:50PM - 2:20PM	Plenary Lecture: Enhancing the targeting of breast cancer prevention Jack Cuzick, Queen Mary's University, London, UK Chair: Mitch Dowsett Hall 1			

<p>Parallel Session 2 2:30PM - 3:45PM</p>	<p><b>Session 2.1 - Genetic testing and optimising patient care</b> Chairs: Ellen Copson and Lesley Turner <b>Optimising clinical and cost utility from genetic testing for breast cancer susceptibility</b> Clare Turnbull, Institute of Cancer Research, London, UK <b>The role of polygenic risk scores in preventing breast cancer</b> Gareth Evans, Manchester University NHS Foundation Trust, Manchester, UK <b>Supporting patient decision making</b> Claire Foster, University of Southampton, Southampton, UK  <b>Hall 1</b></p>	<p><b>Session 2.2 - Can we move from risk-adapted to personalised breast radiotherapy?</b> Chairs: Charlotte Coles and Hilary Stobbart <b>Selecting radiotherapy for DCIS: clinico-pathological data or genomic assays?</b> Elinor Sawyer, Guy's and St Thomas NHS Foundation Trust &amp; King's College London, London, UK <b>Partial breast radiotherapy for women with early breast cancer: 10-year outcomes from IMPORT LOW</b> Anna Kirby, The Royal Marsden Hospital NHS Foundation Trust &amp; Institute of Cancer Research, London, UK <b>Genomic analysis of local recurrences following risk adapted breast radiotherapy in the IMPORT trials defines 'true recurrences' and 'new primaries'</b> Sara Lightowlers, University of Cambridge, Cambridge, UK  <b>Hall 11</b></p>	<p><b>Session 2.3 - Health inequalities and ethnicity and effect on breast cancer outcomes?</b> Chairs: Georgette Oni and Toral Gathani <b>Associations of ethnicity and breast cancer</b> Toral Gathani, University of Oxford, Oxford, UK <b>The health consequences of racism and xenophobia</b> Delan Devakumar, University College London, London, UK <b>Diversity and genetic ancestry effects in the cancer cohort of the UK 100,000 Genomes Project</b> Matt Silver, Genomics England, London, UK  <b>Hall 5</b></p>
<p>3:45PM - 4:15PM</p>	<p>Afternoon refreshment break, exhibition &amp; poster viewing</p>		
<p>Parallel Session 3 4:15PM - 5:30PM</p>	<p><b>Session 3.1 - Personalised breast cancer screening: hype or hope?</b> Chairs: Sarah Vinnicombe and Eddie Gibson <b>Adapting imaging to risk and breast density – time to change</b> Fiona Gilbert, University of Cambridge, Cambridge, UK <b>CanRisk: personalising breast cancer risk prediction for prevention and early detection</b> Antonis Antoniou, University of Cambridge, Cambridge, UK <b>Acceptability and impact of personalised breast screening for women invited and healthcare professionals</b> David French, University of Manchester, Manchester, UK  <b>Hall 1</b></p>	<p><b>Session 3.2 - Genomic assays in ER+ HER2- early breast cancer</b> Chairs: Mitch Dowsett and Zoe Goldthorpe <b>Do genomic assays add information to conventional markers in early breast cancer</b> Oscar Rueda, University of Cambridge, Cambridge, UK <b>Genomic assays for node positive disease, are they ready for routine care</b> Dan Hayes, University of Michigan, Ann Arbor, USA <b>Breast Cancer Index for late relapse and extended adjuvant endocrine therapy</b> Dan Rea, University of Birmingham, Birmingham, UK  <b>Hall 11</b></p>	<p><b>Session 3.3 - UK Clinical Trials showcase</b> Chairs: Stuart McIntosh and Judith Bliss <b>Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography</b> Andy Evans, Royal Derby Hospitals, Derby, UK <b>Surgical margins in breast conserving surgery (BCS) for ductal carcinoma in-situ (DCIS) and clinical outcomes: significant associations with increased recurrence and overall survival</b> John Robertson, University of Nottingham &amp; University Hospitals of Derby &amp; Burton, Derby, UK <b>Trials in Progress updates</b> <b>HER2-RADICAL</b> Iain Macpherson, University of Glasgow, Glasgow, UK <b>ATNEC - Amit Goyal, Royal Derby Hospitals, Derby, UK</b> <b>EndoNET - Ramsey Cutress, University of Southampton, Southampton, UK</b> <b>SMALL - Shelley Potter, Bristol Medical School, Bristol, UK</b> <b>PHOENIX - Andrew Tutt, Institute of Cancer Research &amp; King's College London, London, UK</b> <b>POETIC-A - Stephen Johnston, Royal Marsden Hospital, London, UK</b> <b>OPTIMA - Rob Stein, University College London, London, UK</b> <b>Embedding routine data for enhanced evidence generation from cancer clinical trials</b> Peter Hall, University of Edinburgh, Edinburgh, UK  <b>Hall 5</b></p>
<p>5:40PM - 6:10PM</p>	<p><b>Plenary Lecture: Treatment of ER+ HER2- metastatic breast cancer (The Mary-Jean Mitchell Green Foundation Lecture)</b> Stephen Johnston, Royal Marsden Hospital, London, UK Chair: Delyth Morgan  <b>Hall 1</b></p>		
<p>6:15PM - 7:30PM</p>	<p>Drinks reception and poster viewing - Hall 3</p>		

# Programme - Tuesday 23 January 2024

8:00AM - 8:45AM	<b>Registration</b> Poster viewing and exhibition in Hall 3		
8:00AM - 8:30AM	<b>Satellite Symposium - Gilead</b> Hall 5		
8:45AM - 9:15AM	<b>Plenary Lecture: Breast and axillary surgery after neoadjuvant chemotherapy – the USA perspective</b> Judy Boughey, Mayo Clinic, Rochester, USA Chair: Leena Chagla Hall 1		
Parallel Session 4 9:25AM - 10:40AM	<b>Session 4.1 - Locoregional aspects of neoadjuvant therapy</b> Chairs: Stuart McIntosh and Mairead MacKenzie <b>Optimising breast and axillary surgery after neoadjuvant therapy</b> Walter Weber, University Hospital Basel, Basel, Switzerland <b>Tailoring breast and axillary radiotherapy after neoadjuvant therapy</b> Charlotte Coles, University of Cambridge, Cambridge, UK <b>Role of radiologists in planning loco-regional therapy after neoadjuvant therapy</b> Nisha Sharma, Leeds Teaching Hospital NHS Trust, Leeds, UK Hall 11	<b>Session 4.2 - Lifestyle and breast cancer</b> Chairs: Catherine Harper-Wynne and Ellen Copson <b>Considerations for designing a clinical trial to test a physical activity intervention in women with advanced breast cancer</b> Sam Smith, University of Leeds, Leeds, UK <b>The case for exercise interventions in breast cancer patients</b> Anne May, University Medical Center Utrecht, Utrecht, The Netherlands <b>Preventing and managing breast cancer with weight control – opportunities and challenges</b> Michelle Harvie, Manchester University Hospital Foundation NHS Trust, Manchester, UK Hall 1	<b>Session 4.3 - Supporting health care professionals in the NHS</b> Chairs: Claire Ryan and Sally Kum <b>Why do healthcare professionals need support, and why is it important?</b> Sally Kum, Breast Cancer Now, London, UK <b>The power of collaboration – how patients can support their healthcare professionals</b> Karen Gannon, Patient Advocate <b>Help is out there – how changing ways of working can alleviate pressure</b> 3x case studies from: Jo Beaumont, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK Caroline Leek, Fruitfly Collective, London, UK Michaela Rossman, Breast Cancer Now, London, UK <b>How to take care of yourself</b> Jayne Ellis, EF Training, Hertfordshire, UK <b>Chairs' discussion/summing up, followed by Q&amp;A</b> Claire Ryan, Maidstone and Tunbridge Wells NHS Trust, Kent, UK Sally Kum, Breast Cancer Now, London, UK Hall 5
10:40AM - 11:10AM	<b>Morning refreshment break, exhibition &amp; poster viewing</b>		
11:10AM - 11:40AM	<b>Plenary Lecture: Use of Ki67 and Oncotype prior to surgery to avoid chemotherapy (ADAPT programme)</b> Nadia Harbeck, LMU Breast Center, Munich, Germany Chair: Mitch Dowsett Hall 1		

<p>Parallel Session 5 11:50AM - 1:00PM</p>	<p><b>Session 5.1 - Lessons and opportunities from presurgical studies</b> Chairs: Mitch Dowsett and Nadia Harbeck</p> <p><b>Presurgical studies for guiding breast cancer risk reduction (or prevention)</b> Andrea DeCensi, Galliera Hospital, Genova, Italy</p> <p><b>Challenges for the surgeon from window of opportunity studies – lessons from the POETIC and POETIC A studies</b> John Robertson, University of Nottingham &amp; University Hospitals of Derby &amp; Burton, Derby, UK</p> <p><b>Molecular and clinical lessons from the POETIC study</b> Mitch Dowsett, Royal Marsden Hospital, London, UK</p> <p><b>Hall 11</b></p>	<p><b>Session 5.2 - Triple negative metastatic breast cancer</b> Chairs: Andrew Tutt and DrAmy Guppy</p> <p><b>Identifying and targeting DNA repair deficient forms of metastatic TNBC beyond PARPi in patients with gBRCA 1/2m and in non-gBRCA 1/2m breast cancer</b> Andrew Tutt, Institute of Cancer Research &amp; King's College London, London, UK</p> <p><b>Androgen associated triple negative metastatic breast cancer and effectiveness of targeting it</b> Hervé Bonnefoi, University of Bordeaux, Bordeaux, France</p> <p><b>How to best improve first line metastatic TNBC therapy - What can we learn from the tumour microenvironment in those who have significant residual disease despite NACT + Pembro</b> Sheeba Irshad, King's College London, London, UK</p> <p><b>Hall 1</b></p>	<p><b>Session 5.3 - Early Breast Cancer Trialists' Collaborative Group update</b> Chairs: David Dodwell and David Cameron</p> <p><b>Forty years of the Early Breast Cancer Trialists' Collaborative Group</b> Robert Hills, University of Oxford, Oxford, UK</p> <p><b>Importance and limitations of meta-analysis</b> David Dodwell, University of Oxford, Oxford, UK</p> <p><b>Bringing molecular approaches to Early Breast Cancer Trialists' Collaborative Group</b> Roberto Salgado, Antwerp University Hospital, Antwerp, Belgium</p> <p><b>Hall 5</b></p>	<p><b>Session 5.4 - Young Investigator session</b> Chair: Ellen Copson, Stuart McIntosh and Ingunn Holen</p> <p><b>Crown-like structures are associated with changes in immune cell signatures in patients with primary invasive breast cancer</b> Constantinos Savva, University of Southampton, Southampton, UK</p> <p><b>Developing and feasibility testing of an intervention to support women with adherence to adjuvant endocrine therapy and improve quality of life - the SWEET study</b> Lucy Mcgeagh, Oxford Brookes University, Oxford, UK</p> <p><b>Spatial transcriptomics delineates tumour heterogeneity in NACT triple-negative breast cancer</b> Isobelle Wall, King's College London, London, UK</p> <p><b>Sleepwalking through evolution: a tale of epigenetic adaptation in dormant breast cancer</b> Dalia Rosano, Institute of Cancer Research, London, UK</p> <p><b>Cerenkov luminescence imaging and flexible autoradiography – a first-in-human novel imaging study for intra-operative margin assessment in women undergoing breast-conserving surgery for cancer</b> Aaditya Sinha, King's College London, London, UK</p> <p><b>Targeting ECM remodelling as a therapeutic strategy in invasive lobular carcinoma</b> Renee Flaherty, Institute of Cancer Research, London, UK</p> <p><b>Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse</b> Frances Turrell, Institute of Cancer Research, London, UK</p> <p><b>Hall 8</b></p>
<p>1:10PM - 2:20PM</p>	<p>Lunch, exhibition &amp; poster viewing</p>			

Satellite Symposia 1:20PM - 2:20PM	Satellite Symposium - Novartis Hall 8	Satellite Symposium - MSD Hall 5	Satellite Symposium - Daiichi Sankyo Hall 11
2:30PM - 3:00PM	<b>Plenary Lecture: HCPs' communication with patients about genomic &amp; genetic testing: how to help</b> Lesley Fallowfield, University of Sussex, Sussex, UK Chair: Lesley Turner Hall 1		
Parallel Session 6 3:10PM - 4:25PM	<b>Session 6.1 - Young women with breast cancer</b> Chairs: Judy King and Adrienne Morgan <b>Preservation of fertility in young women after breast cancer treatment</b> Julia Kopeika, Guy's & St Thomas NHS Foundation Trust, London, UK <b>Endocrine therapy for pre-menopausal women</b> Judy King, Royal Free Hospital, London, UK <b>Managing side-effects of young women with early breast cancer</b> Anne Armstrong, The Christie NHS Foundation Trust, Manchester, UK Hall 1	<b>Session 6.2 - What have we learnt from prospective longitudinal epidemiological studies?</b> Chairs: Montse Garcia-Closas and Amy Barrington <b>Generations Study</b> Montse Garcia-Closas, Institute of Cancer Research, London, UK <b>Million Woman Study</b> Gillian Reeves, Oxford University, Oxford, UK <b>Prospective studies of benign breast disease</b> Mustapha Abubakar, National Cancer Institute, Rockville, USA Hall 11	<b>Session 6.3 - New developments in breast cancer diagnosis and treatment</b> Chairs: Sarah Pinder and Sarah Vinnicombe <b>Circulating tumour DNA dynamics for early assessment of recurrence risk</b> Nicholas Turner, Institute of Cancer Research, London, UK <b>Extending the promise of digital pathology</b> Sarah Pinder, Kings College London, London, UK <b>What would GRAIL mean for breast cancer detection and management</b> Mark Middleton, University of Oxford, Oxford, UK Hall 5
4:25PM - 4:30PM	Close		

Please note, all speakers, timings and content are subject to change.

## Notes

## Our Partners

